• COVID-19:
    • Mild-moderate:
      • Adults: IV 200mg *1, then 100mg OD *2/7
        • Start ASAP w/in 7 days of symptom onset
      • Child ≥28 days:
      • (3-39kg): IV 5mg/kg/dose *1, then 2.5mg/kg/dose OD *2/7
    • Severe:
      • Adult: IV 200mg *1, then 100mg OD *4/7
        • May give with baricitinib
      • Child ≥28 days:
        • (3-39kg): IV 5mg/kg/dose *1, then 2.5mg/kg/dose OD *4-9 days depending on mechanical ventilation
  • Injection:
    • 100mg/vial
  • Do not administer simultaneously in IV line with any other medication
  • Infuse IV over 30-120 minutes

Antiviral

It inhibits SARS-CoV-2 RNA-dependent RNA polymerase (RdRp), which is essential for viral replication. Remdesivir metabolises to remdesivir triphosphate (RDV-TP). RDV-TP acts as an analog of adenosine triphosphate (ATP) and competes with the natural ATP substrate for incorporation into nascent RNA chains by the SARS-CoV-2 RNA-dependent RNA polymerase, which results in delayed chain termination during replication of the viral RNA.

  • Increased transaminase levels
  • Hepatitis
  • Angioedema
  • Diaphoresis
  • Dyspnoea
  • Bradycardia or tachycardia
  • Hypotension or hypertension
  • Nausea
  • Rash
  • Fever
  • Shivering
  • Vomiting
  • Hypoxia
  • Wheezing
  • Prolonged prothrombin time/INR
  • Hypersensitivity to class/components
  • None restricted

                                   Drug Status

Availability Prescription only
Pregnancy Use only when benefits outweigh risks
Breastfeeding May be used
Schedule Not scheduled
BRAND NAME STRENGTH FORMULATION PACK SIZE MANUFACTURER DISTRIBUTOR
Remdac 100mg Injection 1’s Cadila Pharma Cadila Pharma